SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
MDCX

Medicus Pharma Ltd. (NASDAQ:MDCX)

CA · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.14-$0.03 (-2.16%)
 
Market cap
$1.63M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 15, 2024
Market Cap$1.63M-98.8%
Revenue (ttm)$0
Net Income-$44.03M-49.1%
EPS-$58.61+24.9%
Shares Out1.43M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume86,719
Open$1.09
Previous Close$1.16
Day's Range$1.09 - $1.20
52-Week Range$1.06 - $114.00
Betan/a
AnalystsBuy
Price Target$1.00(-11.89%)
Earnings DateMar 24, 2027
-1.72% (1D)
No price history available.

About MDCX

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

Address
300 Conshohocken State Road, West Conshohocken, PA, 19428, CA
Market Cap
2 million
Employees
16
Industrial Classification
Biotechnology
Financial Health Score
Distressed
From MDCX’s reported statements · Q3 2026 (trailing 12 months) · 3 of 5 pillars

Next catalysts

1 Day
-2.16%
5 Days
-42.68%
1 Month
-56.68%
6 Months
-92.43%
1 Year
-98.85%

$MDCX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in MDCX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by MDCX's directors and management

Net Shares Purchased by Insiders−1−102025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

MDCX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New MDCX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to MDCX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from MDCX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
85
News & Sentiment
38% of score
72

News check: Regained Nasdaq compliance, secured $4.25M financing, executed $10.5M debt exchange, and strengthened pipeline focus on Pfizer-licensed cancer drug amid cost optimization.

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.